Recombinant Human CYB5R1 protein(Leu29-Tyr305), His-tagged

• Cat.No.: CYB5R1-551H
• Product Overview: Recombinant Human CYB5R1 (Q9UHQ9) (Leu 29-Tyr 305) was expressed in E. coli, with a polyhistidine tag at the N-terminus.

Specification

• Species: Human
• Source: E.coli
• Tag: His
• Protein Length: Leu29-Tyr305
• Form: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
• Molecular Mass: The recombinant human CYB5R1 consisting of 292 amino acids and migrates as an approximately 33.5 kDa band in SDS-PAGE under reducing conditions as predicted.
• Purity: > 97 % as determined by SDS-PAGE
• Storage: Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Gene Information

• Gene Name: CYB5R1 cytochrome b5 reductase 1 [ Homo sapiens ]
• Official Symbol: CYB5R1
• Synonyms: CYB5R1; cytochrome b5 reductase 1; NAD(P)H:quinone oxidoreductase type 3, polypeptide A2 , NQO3A2; NADH-cytochrome b5 reductase 1; humb5R2; NAD(P)H:quinone oxidoreductase type 3 polypeptide A2; NAD(P)H:quinone oxidoreductase type 3, polypeptide A2; B5R1; B5R.1; NQO3A2
• Gene ID: 51706
• mRNA Refseq: NM_016243
• Protein Refseq: NP_057327
• MIM: 608341
• UniProt ID: Q9UHQ9

Case Study

Case 1: Urano Y, et al. Free Radic Biol Med. 2025

25-OHC triggers ferroptosis in Schwann cells by suppressing SREBP-mediated GPX4 expression, upregulating lipid peroxidation enzymes (CYB5R1/POR), and depleting glutathione via CHAC1. This redox imbalance enhances sensitivity to ferroptosis inducers, linking oxysterol dysregulation to neurodegenerative pathways in ALS. Findings reveal 25-OHC’s role in glial cell death, offering insights into therapeutic targeting of cholesterol metabolism in neurodegeneration.

Fig1. Cells were transfected with CYB5R1 (siCYB5R1) or negative control (siNC) siRNA oligo.

Fig2. Whole-cell lysates were immunoblotted with appropriate antibodies as indicated.

Case 2: Zhang Q, et al. Transl Oncol. 2024

CYB5R1 drives drug resistance and stemness in gastric cancer, correlating with poor prognosis in high mRNAss patients. WGCNA and differential analysis identified CYB5R1 as a biomarker (AUC=0.83) linked to NFS1-mediated tumorigenesis and immune infiltration. Silencing CYB5R1 reduced spheroid formation and invasion, highlighting its role in cancer stem cell pathways and therapeutic targeting for overcoming chemotherapy resistance in gastric malignancies.

Fig1. Analysis of the protein expression levels of CYB5R1 in different GC cell lines by western blot assay.

Fig2. Dose-response curves of the cell lines co-transfected with NFS1 OE and shCYB5R1.

Application

1. Therapeutic and Research Applications of Recombinant CYB5R1 Protein Recombinant CYB5R1 (NADH-cytochrome b5 reductase 1) protein is a critical tool for studying redox regulation and drug resistance mechanisms in cancers, particularly gastric cancer (GC). Its role in modulating lipid peroxidation and ferroptosis pathways positions it as a target for overcoming chemotherapy resistance linked to cancer stem cells (CSCs). Preclinical models utilize recombinant CYB5R1 to dissect its interaction with NFS1, a key iron-sulfur cluster enzyme, to develop inhibitors that disrupt CSC-driven tumorigenesis and metastasis. 2. Drug Development and Mechanistic Insights In drug discovery, recombinant CYB5R1 enables high-throughput screening for compounds targeting redox imbalance in cancers. Studies reveal its involvement in macrophage infiltration and immune evasion, offering strategies to enhance immunotherapy efficacy. By mimicking CYB5R1 overexpression in in vitro systems, researchers identify pathways that promote spheroid formation and invasion, accelerating therapies for aggressive GC subtypes. 3. Biotechnological and Diagnostic Innovations Beyond oncology, recombinant CYB5R1 supports studies on neurodegenerative diseases, where redox dysregulation contributes to pathologies like ALS. Its enzymatic activity aids in industrial applications, including biofuel synthesis and enzymatic cascades. Additionally, CYB5R1 levels are explored as biomarkers for predicting drug response and prognosis, advancing personalized medicine approaches in oncology and metabolic disorders.

Fig1. Schematic of the proposed mechanism for 25-OHC-induced ferroptosis in IMS32 cells. (Yasuomi Urano, 2025)